Medical researchers generally consider anecdotal or subjective accounts of health improvement to be of lesser value than other types of scientific evidence. They want to see numbers, scans, statistically significant data. “Metabolomics” is a technique to measure how the body is responding on a cellular level to a particular treatment. Dr. Bonni Goldstein describes a groundbreaking study involving autistic children whose aberrant biomarkers shifted dramatically toward the neurotypical range when medical cannabis was administered. These quantifiable changes corresponded to positive mood and behavioral outcomes. This was the first clinical experiment that combined cannabis and metabolomics. It has huge implications for refining and advancing cannabinoid treatment strategies that could be applied to a wide range of conditions.https://youtu.be/375Bcx6cJIw
